Warner-lambert Company

Millennium Pharmaceuticals Limited

Steven Robert Miller

David T Connor

Paul C Unangst

Lawrence D Wise

Bharat Kalidas Trivedi

Bruce D Roth

Larry D Bratton

Stephen J Johnson

Suzanne Ross Kesten

Jay R Luly

Alexander James Bridges

Catherine R Kostlan

Kenneth Gordon Carson

Thomas R Belliotti

Yuntao Song

Thomas Capiris

Joseph Edwin Low

Kuai-Lin Sun

Jie Jack Li

The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.

MCP-1 receptor antagonists and methods of use thereof

Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.

Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

The instant invention is a series of compounds which are MCP-1 receptor antagonists of Formula I

Chemokine receptor antagonists

This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.

Method of treating psychosis and schizophrenia

Compounds and method of treating psychosis and schizophrenia

1,2,3,4-Tetrahydro-chromeno�3,4-c!pyridin-5-ones of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.5 include hydrogen, alkyl, alkoxy, hydroxy, halo, nitro, amino, and trifluoromethyl; R.sub.4 is unsubstituted or substituted phenyl, pyridyl, or quinolinyl; and n is 0 to 4, are useful to treat psychosis in mammals, particularly schizophrenia.

Antipsychotic method utilizing certain

The present invention is novel compounds which are 2-carbonyl substituted-5-hydroxy-1,3-pyrimidines and pharmaceutically acceptable acid addition or base salts thereof, pharmaceutical compositions and methods of use therefor. The invention compounds are now found to have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase providing treatment of conditions advantageously affected by such inhibition including inflammation, arthritis, pain, fever and the like. Thus, the present invention is also a pharmaceutical composition or method of manufacturing a pharmaceutical composition for the use of treating the noted conditions.

2-carbonyl substituted-5-hydroxy-1, 3-pyrimidines as antiinflammatory

Growing community of inventors

Ann Arbor, MI, United States of America

Steven Robert Miller